Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2001 1
2002 1
2003 1
2004 1
2005 4
2006 12
2007 9
2008 1
2009 1
2010 5
2011 3
2012 1
2014 1
2015 4
2016 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Among authors: heffernan mp. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Cutaneous epithelioid angioleiomyoma.
Heffernan MP, Smoller BR, Kohler S. Heffernan MP, et al. Am J Dermatopathol. 1998 Apr;20(2):213-7. doi: 10.1097/00000372-199804000-00021. Am J Dermatopathol. 1998. PMID: 9557795 Review.
Alefacept for psoriasis.
Heffernan MP, Leonardi CL. Heffernan MP, et al. Semin Cutan Med Surg. 2010 Mar;29(1):53-5. doi: 10.1016/j.sder.2010.03.002. Semin Cutan Med Surg. 2010. PMID: 20430308 Review. No abstract available.
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.
Pimentel MA, Li MM, Noe MH, Latour E, Seminario-Vidal L, Greiling T, Shinkai K, Hamilton A, Alavi A, Bolognia JL, Cowen EW, Dominguez A, Fernandez AP, Fivenson D, Huang WW, Madigan LM, Mauskar M, Means AD, Nelson CA, Patsatsi A, Pugliese D, Rojek NW, Rosenbach M, Smith GP, Swerlick RA, Heffernan MP, Mostaghimi A, Ortega-Loayza AG. Pimentel MA, et al. Among authors: heffernan mp. Br J Dermatol. 2023 Mar 30;188(4):566-568. doi: 10.1093/bjd/ljac137. Br J Dermatol. 2023. PMID: 36746554 No abstract available.
Antinuclear antibodies in dermatology.
Heffernan MP, Do JH, Mehta J. Heffernan MP, et al. Semin Cutan Med Surg. 2001 Mar;20(1):2-13. doi: 10.1053/sder.2001.23089. Semin Cutan Med Surg. 2001. PMID: 11308133 Review.
Innovative uses of rituximab in dermatology.
Carr DR, Heffernan MP. Carr DR, et al. Among authors: heffernan mp. Dermatol Clin. 2010 Jul;28(3):547-57. doi: 10.1016/j.det.2010.03.002. Dermatol Clin. 2010. PMID: 20510764 Review.
Facial signs of systemic disease.
Nelson MM, Heffernan MP. Nelson MM, et al. Among authors: heffernan mp. Facial Plast Surg Clin North Am. 2003 May;11(2):175-95. doi: 10.1016/S1064-7406(02)00048-2. Facial Plast Surg Clin North Am. 2003. PMID: 15062272 Review. No abstract available.
Off-label uses of rituximab in dermatology.
Carr DR, Heffernan MP. Carr DR, et al. Among authors: heffernan mp. Dermatol Ther. 2007 Jul-Aug;20(4):277-87. doi: 10.1111/j.1529-8019.2007.00141.x. Dermatol Ther. 2007. PMID: 17970893 Review.
Chronic cutaneous fusariosis.
Gardner JM, Nelson MM, Heffernan MP. Gardner JM, et al. Among authors: heffernan mp. Arch Dermatol. 2005 Jun;141(6):794-5. doi: 10.1001/archderm.141.6.794. Arch Dermatol. 2005. PMID: 15967939 No abstract available.
46 results